Zinc Finger Nuclease Clinical Trial

ARVO 2015 Annual Meeting Abstracts
Autologous retinal (clinical trial 1) and iris pigment epithelial cells (clinical trial 2) Methods: Sixteen Zinc Finger Nuclease (ZFN) pairs were designed to target the 3’UTR of human CRX gene without disrupting its coding sequence. ... Return Doc

Advances In Antiretroviral Therapy - IAS-USA
This trial enrolled 38 HIV-infected participants, of whom 97% were men; mean HIV-1 RNA level was 4.5 log 10 copies/mL; mean CD4+ count, 478 cells/µL. As expected including integrase strand transfer inhibitors (InSTIs) and zinc-finger nucleases disrupting CC chemokine receptor 5 (CCR5 ... Return Doc

Companies Vie For A Cut Of The Gene-editing Market
New zinc finger nuclease–based therapies. In March, the California biotech reported preliminary phase 1 trial results showing that its HIV treatment, which uses editing to turn off the gene for the receptor on the cell membrane Sangamo’s zinc finger nucleases (ZFNs), ... Document Viewer

Transcript Science Immunotherapy Webinar On 18 Nov 2013
Science Immunotherapy webinar on 18 Nov 2013 zinc‐finger nuclease modified CD4 T‐cells. A warm welcome to, Dr. opportunity to share our data and clinical trial results with the ... Fetch Document

Supplementary Appendix - NATAP
Supplementary Appendix Genome Editing with Zinc Finger Nuclease Modified Autologous CD4 T-cells .. 1 Expanded Methods clinical protocol is included as a Supplementary Appendix. The cells were manufactured as described. 1. ... Retrieve Document

Is “Cure” Still A Four-Letter Word? participants’ blood and modified using a zinc finger nuclease, a protein engineered to cut DNA strands at the region coding for the CCR5 gene. diversity among clinical trial participants: ... Document Viewer

MONDAY, OCTOBER 11, 2010 B I W
CASPALLO: Phase I Clinical Trial of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene after Haploidentical Stem Cell: Transplantation: Zinc Finger Nuclease Mediated Disruption of Glucocorticoid Regulation in Therapeutic Human T Cells: 3. 12:15-12:35 . ... Fetch Content

The State Stem Cell Agency CIRM/Regenerative Medicine ...
Challenges in clinical trial design for first-in-human studies • Issues across therapeutic areas and cell types: – setting objectives for the trial; choosing the patient population; selecting doses and delivery; selecting ... View Document

Genome Editing Of Human Embryonic Stem Cells And Induced ...
Therapeutic potential and their subsequent clinical applications. Editorial, we used genome editing with zinc finger nuclease (ZFN) technology to derived from zinc finger nuclease (ZFN)–edited human embryonic stem cells (hESCs). A. and . B, CMs derived from ZFN-edited cells (top ... Fetch Doc

Gene Therapy - Wikipedia, The Free Encyclopedia
Using techniques such as zinc finger nucleases using antisense / triple helix anti IGF-I approach was registered in 2002 by Wiley gene therapy clinical trial - n˚ 635 and 636. The approach has shown promising In May researchers announced the first gene therapy trial for inherited ... Read Article

Enhancing The IQ Of CAR–modified T Cells
These strategies and the results of an ongoing clinical trial of adoptive T cell therapy targeting WT1 in patients with leukemia will be described. Enhancing the IQ of CAR the approach taken to move these cells into Phase I clinical trials. Zinc Finger Nuclease mediated genomic editing of ... Document Viewer

PowerPoint Presentation
Zinc finger. TAL Effector Nuclease. CRISPR /Cas9 . megaTAL. Hematopoietic Stem Cell approach targeting CCR5 about to begin a clinical trial. Both enroll patients whose virus has been tested to ensure that CCX4 tropic virus is not present. Calimmune. ... Access Doc

Zinc finger Chimera - Wikipedia, The Free Encyclopedia
Zinc finger chimera Zinc finger protein chimera are An ongoing clinical trial is evaluating Zinc finger nucleases that disrupt the CCR5 gene in CD4+ human T-cells as a potential treatment for HIV/AIDS. Zinc finger nuclease; Zinc finger protein transcription factor; ... Read Article

SANGAMO BIOSCIENCES INC - Shareholder
Additional data from the Phase 1b clinical trial (S B-509- 401) were presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD), and pathways. For more information on Sigma- Aldrich's CompoZr zinc finger nuclease technology ... Doc Viewer

Sangamo BioSciences Presents Data At The 2015 American ...
Therapy market and we look forward to beginning our first clinical trial of the platform.€ We intend to move The NHP studies demonstrate that Sangamo's zinc finger nuclease (ZFN) technology can be used to precisely insert a copy that can be edited with zinc finger nucleases ... View Full Source

Developing Resistance Against HIV By Modifying The CCR5 Receptor
Keywords: HIV, AIDS, CCR5 coreceptor, CD4 receptor, gene therapy, zinc finger nuclease. INTRODUCTION he gp120 protein of the HIV has to bind the CD4 receptor as well as the coreceptor CCR5 or CXCR4. clinical trial ex vivo investigation.14 Phase 1 studies have ... Retrieve Full Source

HIV CURE-RELATED CLINICAL RESEARCH WORKSHOP
Valproic acid • viral replicationviral suppressionvorinostat • zinc finger nuclease • zoonotic pathogens HIV CURE-RELATED CLINICAL RESEARCH WORKSHOP 20−21 April, 2011 Baltimore, MD The HIV Cure-Related Clinical Research Workshop was sponsored by ... Fetch Document

Hatfield, Hertfordshire, AL10 9AB, UK - Link.springer.com
Hatfield, Hertfordshire, AL10 9AB, UK For other titles published in this series, go to the first Phase I Clinical Trial of an ATF was initiated by Sangamo Biosciences in 2005. In Vitro Assessment of Zinc Finger Nuclease Activity ... Access Doc

HOPE, HYPE & REALITY: ZINC FINGER GENE THERAPY TO CONTROL OR ...
Of his company’s zinc finger nuclease (ZFN)-based genome editing technology in people. CLINICAL TRIAL RESULTS!!! PART 2 - Duration: 10:14. imstillstanding2043 8,927 views. 10:14 Copy of HOPE, HYPE & REALITY: ZINC FINGER GENE THERAPY TO CONTROL OR CURE HIV - Duration: ... View Video

Genome Engineering At The Dawn Of The Golden Age
Zinc-finger nuclease (ZFN); T, transcription activator–like effector nuclease (TALEN); in clinical trial. www.annualreviews.org • Genome Engineering at the Dawn of the Golden Age 157. GG14CH07-Segal ARI 26 July 2013 12:46 ... Access Full Source